Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance-Reference-Cited by-同舟云学术

Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance

Published:2020-11-03 Issue:2 Volume:75 Page:
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Jain Akshay B.¹^ORCID,Ali Amar²,Gorgojo Martínez Juan J.³^ORCID,Hramiak Irene⁴,Kavia Ketan⁵,Madsbad Sten⁶^ORCID,Potier Louis⁷,Prohaska Ben D.⁸,Strong Jodi L.⁹,Vilsbøll Tina¹⁰

Affiliation:

1. University of British Columbia Surrey BC Canada

2. Oakenhurst Medical Practice Blackburn UK

3. Department of Endocrinology and Nutrition Hospital Universitario Fundacion Alcorcón Alcorcón Spain

4. Western University London ON Canada

5. Manor Park Medical Practice Leicester UK

6. Department of Endocrinology Hvidovre Hospital Hvidovre Denmark

7. Bichat HospitalAPHPUniversité de Paris Paris France

8. Northern Nevada Endocrinology Reno NV USA

9. Ascension Medical Group Stevens Point WI USA

10. Steno Diabetes Center Copenhagen Copenhagen Denmark

Funder

Novo Nordisk

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.13731

Reference73 articles.

1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

2. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

3. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary

4. U.S. Food & Drug Administration.Prescibing information: BYETTA®(exenatide) injection;2009.https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf. Accessed February 5 2020.

5. U.S. Food & Drug Administration.Prescribing information: ADLYXIN®(lixisenatide) injection for subcutaneous use;2016.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471orig1s000lbl.pdf. Accessed February 5 2020.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study;Journal of Diabetes Research;2024-01-04

2. Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study;Frontiers in Endocrinology;2023-10-24

3. Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial;BMJ Open Diabetes Research & Care;2023-05

4. Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages;Clinical Diabetes;2023-04-07

5. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus;Journal of Clinical Medicine;2022-12-24